Recognizing that therapeutic intervention in earlier phases of ALS has the potential to yield the greatest clinical benefit, ATLAS, together with data from the VALOR study and its open-label extension study, will inform the optimal timing of treatment initiation in SOD1-ALS. Here, SOD1 is linked to amyotrophic lateral sclerosis.